Otago Centre for Theoretical Studies in Psychiatry and Neuroscience (OCTSPAN), Department of Anatomy and Structural Biology, School of Medical Sciences, University of Otago, P.O.Box 913, Dunedin, New Zealand.
Curr Neuropharmacol. 2009 Dec;7(4):315-30. doi: 10.2174/157015909790031184.
Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be expected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine (notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. Clinical response to neuroleptics varies widely at any given plasma level. Haase's "neuroleptic threshold" concept suggests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses presented here suggest that antipsychotic actions are not subject to a sharp "all-or-none" threshold but increase over a small dose range. This concept could provide a method for quantitative determination of individualized optimal doses.
快速发作的精神病性反弹在大多数抗精神病药物停药时并不常见,这可能是因为这些药物对其最终靶受体具有(假设的)间接作用。而氯氮平停药时更常见快速发作的精神病性反应,如果它的作用是直接的,这是可以预期的。除氯氮平以外的其他药物(特别是硫利达嗪)可能与氯氮平具有迄今为止尚未被认识到的相似之处(但没有粒细胞缺乏的危险),并且可能对难治性精神病的治疗有用。喹硫平仅符合氯氮平样药物的部分标准。在任何特定的血浆水平下,神经阻滞剂的临床反应差异很大。Haase 的“神经阻滞剂阈值”概念表明,产生最小运动副作用的剂量会产生大部分或全部治疗益处,但这里提出的分析表明,抗精神病作用不受明显的“全有或全无”阈值的限制,而是在小剂量范围内增加。这一概念可以为确定个体化最佳剂量提供一种定量方法。